Furthermore, intratumorally injected interleukin 2 (IL-2) and IL-2-containing agents have shown promising response rates and have been used to treat melanoma skin metastases for years.13, –15 However, the number of publications reporting data on patients treated with local IL-2 therapy is limited. The gene discussed is IL2; the disease is melanoma.